Literature DB >> 2311181

Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl)amine.

M Takahashi1, F Furukawa, K Toyoda, H Sato, R Hasegawa, K Imaida, Y Hayashi.   

Abstract

The effects of prostaglandin synthesis inhibitors on development of N-nitrosobis(2-oxopropyl)amine (BOP)-initiated pancreatic tumors were investigated. Female Syrian golden hamsters were given five weekly s.c. injections of BOP (10 mg/kg body weight) during the first 5 weeks and then given 20 p.p.m. indomethacin in the drinking water, 0.25% phenylbutazone in the diet, 1% aspirin in the diet, or no treatment (control group). The resultant incidence of pancreatic carcinoma at week 32 was significantly lower (P less than 0.05) in animals receiving phenylbutazone (36.8%) than in the controls (71.4%) and the numbers of carcinomas per hamster were significantly reduced by indomethacin (0.63) and phenylbutazone (0.58) treatment compared with the control group value (1.29). Aspirin also showed a tendency to decrease pancreatic tumor incidence, but this was not significant. Thus, prostaglandin synthesis inhibitors reduce the development of pancreatic cancer when administered during the post-initiation phase in this animal model.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2311181     DOI: 10.1093/carcin/11.3.393

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  24 in total

Review 1.  Chemoprevention strategies for pancreatic cancer.

Authors:  Silvia D Stan; Shivendra V Singh; Randall E Brand
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-05-04       Impact factor: 46.802

2.  Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors.

Authors:  T Koshiba; R Hosotani; Y Miyamoto; M Wada; J U Lee; K Fujimoto; S Tsuji; S Nakajima; R Doi; M Imamura
Journal:  Int J Pancreatol       Date:  1999-10

Review 3.  Pathogenesis of pancreatic cancer: lessons from animal models.

Authors:  L Charles Murtaugh
Journal:  Toxicol Pathol       Date:  2013-10-31       Impact factor: 1.902

4.  Antioxidant properties of aspirin: characterization of the ability of aspirin to inhibit silica-induced lipid peroxidation, DNA damage, NF-kappaB activation, and TNF-alpha production.

Authors:  X Shi; M Ding; Z Dong; F Chen; J Ye; S Wang; S S Leonard; V Castranova; V Vallyathan
Journal:  Mol Cell Biochem       Date:  1999-09       Impact factor: 3.396

5.  Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia.

Authors:  Pamela L Crowell; C Max Schmidt; Michele T Yip-Schneider; Jesse J Savage; Dean A Hertzler; William O Cummings
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

6.  A novel combinatorial nanotechnology-based oral chemopreventive regimen demonstrates significant suppression of pancreatic cancer neoplastic lesions.

Authors:  B Karthik Grandhi; Arvind Thakkar; Jeffrey Wang; Sunil Prabhu
Journal:  Cancer Prev Res (Phila)       Date:  2013-09-26

7.  Inhibition of activator protein 1 activity and neoplastic transformation by aspirin.

Authors:  Z Dong; C Huang; R E Brown; W Y Ma
Journal:  J Biol Chem       Date:  1997-04-11       Impact factor: 5.157

8.  Expression of cyclooxygenase-2 in human esophageal squamous cell carcinomas.

Authors:  Jian-Gang Jiang; Jiang-Bo Tang; Chun-Lian Chen; Bao-Xing Liu; Xiang-Ning Fu; Zhi-Hui Zhu; Wei Qu; Katherine Cianflone; Michael-P Waalkes; Dao-Wen Wang
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

9.  Altered hepatic eicosanoid concentrations in rats treated with the peroxisome proliferators ciprofibrate and perfluorodecanoic acid.

Authors:  M W Wilson; L T Lay; C K Chow; H H Tai; L W Robertson; H P Glauert
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

10.  Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer.

Authors:  A Juuti; J Louhimo; S Nordling; A Ristimäki; C Haglund
Journal:  J Clin Pathol       Date:  2006-02-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.